News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Management Board and the Supervisory Board of the GENEART AG Recommends the Acceptance of the Applied Biosystems (ABI)/Life Technologies (LIFE) Voluntary Public Offer


4/16/2010 11:18:22 AM

REGENSBURG, GERMANY--(Marketwire - April 16, 2010) - Geneart AG / The Management Board and the Supervisory Board of the GENEART AG Recommends the Acceptance of the Applied Biosystems/Life Technologies Voluntary Public Offer processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Regensburg, April 16, 2010 - The Management Board and the Supervisory Board of GENEART AG have announced their joint statement with respect to the voluntary public offer by Applied Biosystems Deutschland GmbH to the shareholders of GENEART AG. This joint statement is in reference to the offer document published by the Applied Biosystems Deutschland GmbH (affiliate of the Life Technologies Group) on April 13, 2010.

The Management Board's and the Supervisory Board's joint statement may be downloaded from GENEART AG's website at www.geneart.com. It is explicitly advised that the German Takeover Act (WpÜG) does not apply to the offer for acquisition of GENEART AG shares. This is not a statement pursuant to the WpÜG.

For further inquiries, please contact:
Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: (0)941-942 76-417
Fax: (0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: (0)89-8896906-10
Fax: (0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information:

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

About GENEART AG:

In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, the US-American Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of 3.3B U.S. dollars and about 9,000 employees, is majority shareholder of GENEART AG.

[HUG#1404472]

Geneart AG
Josef-Engert-Str.11 Regensburg Germany

Press release (PDF): http://hugin.info/136633/R/1404472/358578.pdf




Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES